review article | Q7318358 |
scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1042711082 |
P356 | DOI | 10.1007/S11894-999-0085-4 |
P8608 | Fatcat ID | release_p2fzrpt3rvfnnav7yet2665js4 |
P698 | PubMed publication ID | 10980925 |
P2093 | author name string | Lee YM | |
Kaplan MM | |||
P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. | Q44951192 | ||
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. | Q51597193 | ||
Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. | Q54072767 | ||
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
Ursodeoxycholic acid for primary sclerosing cholangitis | Q68095108 | ||
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | Q72503309 | ||
Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study | Q73167014 | ||
P433 | issue | 1 | |
P921 | main subject | ascending cholangitis | Q603644 |
primary sclerosing cholangitis | Q1058608 | ||
primary biliary cholangitis | Q1072420 | ||
sclerosing cholangitis | Q18554727 | ||
P304 | page(s) | 38-41 | |
P577 | publication date | 1999-02-01 | |
P1433 | published in | Current gastroenterology reports | Q26842032 |
P1476 | title | Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid | |
P478 | volume | 1 |
Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
Q34936778 | Evolving new therapies of autoimmune hepatitis |
Q34515652 | Primary biliary cirrhosis: new thoughts on pathophysiology and treatment |
Q44451209 | Sclerosing cholangitis as a complication of Langerhans'cell histiocytosis |
Q41701715 | Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report |
Search more.